Protocol Ledger

NCT07197034 · Phase III · TERMINATED

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

Interventional Phase III clinical trial protocol NCT07197034 sponsored by Aardvark Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-23 Enrollment: 19 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07197034
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)19 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07197034
Protocol FieldVerified Registry Value
NCT IdentifierNCT07197034
Consolidated Lead SponsorAardvark Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment19 participants (ACTUAL)
Registered Start Date2024-07-23
WhyStopped ClassificationFunding / COVID / Operational

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI